1887

Chapter 111 : Mechanisms of Resistance to Antiviral Agents

Authors: Robert W. Shafer, Sunwen Chou
Content Type: Reference
Publication Year: 2015

Category: Clinical Microbiology

MyBook is a cheap paperback edition of the original book and will be sold at uniform, low price.

Preview this chapter:
Preview Magnify
Zoom in
Zoomout

Mechanisms of Resistance to Antiviral Agents, Page 1 of 2

| /docserver/preview/fulltext/10.1128/9781555817381/9781555817381.ch111-1.gif /docserver/preview/fulltext/10.1128/9781555817381/9781555817381.ch111-2.gif

Abstract:

Understanding the mechanisms of viral drug resistance is critical for clinical management of individuals receiving antiviral therapy, for developing new antiviral drugs, and for drug resistance surveillance. This chapter reviews the mechanisms of resistance to antiviral drugs used to treat seven common viral infections: herpes simplex virus, cytomegalovirus, varicella-zoster virus, human immunodeficiency virus type 1, influenza A and B viruses, hepatitis B virus, and hepatitis C virus.

Citation: Shafer R, Chou S. 2015. Mechanisms of Resistance to Antiviral Agents, p 1894-1912. In Jorgensen J, Pfaller M, Carroll K, Funke G, Landry M, Richter S, Warnock D (ed), Manual of Clinical Microbiology, Eleventh Edition. ASM Press, Washington, DC. doi: 10.1128/9781555817381.ch111
Highlighted Text: Show | Hide
Loading full text...

Full text loading...

References

/content/book/10.1128/9781555817381.mcm11.ch111
1. Reardon JE,, Spector T. 1989. Herpes simplex virus type 1 DNA polymerase. Mechanism of inhibition by acyclovir triphosphate. J Biol Chem 264: 7405– 7411.
2. Earnshaw DL,, Bacon TH,, Darlison SJ,, Edmonds K,, Perkins RM,, Vere Hodge RA. 1992. Mode of antiviral action of penciclovir in MRC-5 cells infected with herpes simplex virus type 1 (HSV-1), HSV-2, and varicella-zoster virus. Antimicrob Agents Chemother 36: 2747– 2757.
3. Piret J,, Boivin G. 2011. Resistance of herpes simplex viruses to nucleoside analogues: mechanisms, prevalence, and management. Antimicrob Agents Chemother 55: 459– 472.
4. Andrei G,, Snoeck R. 2013. Herpes simplex virus drug-resistance: new mutations and insights. Curr Opin Infect Dis 26: 551– 560.
5. Burrel S,, Aime C,, Hermet L,, Ait-Arkoub Z,, Agut H,, Boutolleau D. 2013. Surveillance of herpes simplex virus resistance to antivirals: A 4-year survey. Antiviral Res 100: 365– 372.
6. Sarisky RT,, Quail MR,, Clark PE,, Nguyen TT,, Halsey WS,, Wittrock RJ,, O’Leary Bartus J,, Van Horn MM,, Sathe GM,, Van Horn S,, Kelly MD,, Bacon TH,, Leary JJ. 2001. Characterization of herpes simplex viruses selected in culture for resistance to penciclovir or acyclovir. J Virol 75: 1761– 1769.
7. Sauerbrei A,, Deinhardt S,, Zell R,, Wutzler P. 2010. Phenotypic and genotypic characterization of acyclovir-resistant clinical isolates of herpes simplex virus. Antiviral Res 86: 246– 252.
8. Andrei G,, Georgala A,, Topalis D,, Fiten P,, Aoun M,, Opdenakker G,, Snoeck R. 2013. Heterogeneity and evolution of thymidine kinase and DNA polymerase mutants of herpes simplex virus type 1: implications for antiviral therapy. J Infect Dis 207: 1295– 1305.
9. Pan D,, Kaye SB,, Hopkins M,, Kirwan R,, Hart IJ,, Coen DM. 2013. Common and new acyclovir resistant herpes simplex virus-1 mutants causing bilateral recurrent herpetic keratitis in an immunocompetent patient. J Infect Dis 209: 345– 349.
10. Chen SH,, Pearson A,, Coen DM,, Chen SH. 2004. Failure of thymidine kinase-negative herpes simplex virus to reactivate from latency following efficient establishment. J Virol 78: 520– 523.
11. Grey F,, Sowa M,, Collins P,, Fenton RJ,, Harris W,, Snowden W,, Efstathiou S,, Darby G. 2003. Characterization of a neurovirulent aciclovir-resistant variant of herpes simplex virus. J Gen Virol 84: 1403– 1410.
12. Morfin F,, Thouvenot D,, Aymard M,, Souillet G. 2000. Reactivation of acyclovir-resistant thymidine kinase-deficient herpes simplex virus harbouring single base insertion within a 7 Gs homopolymer repeat of the thymidine kinase gene. J Med Virol 62: 247– 250.
13. Saijo M,, Suzutani T,, Itoh K,, Hirano Y,, Murono K,, Nagamine M,, Mizuta K,, Niikura M,, Morikawa S. 1999. Nucleotide sequence of thymidine kinase gene of sequential acyclovir-resistant herpes simplex virus type 1 isolates recovered from a child with Wiskott-Aldrich syndrome: evidence for reactivation of acyclovir- resistant herpes simplex virus. J Med Virol 58: 387– 393.
14. Griffiths A. 2011. Slipping and sliding: frameshift mutations in herpes simplex virus thymidine kinase and drug-resistance. Drug Resist Updat 14: 251– 259.
15. Pan D,, Coen DM. 2012. Quantification and analysis of thymidine kinase expression from acyclovir-resistant G-string insertion and deletion mutants in herpes simplex virus-infected cells. J Virol 86: 4518– 4526.
16. Stránská R,, Schuurman R,, Nienhuis E,, Goedegebuure IW,, Polman M,, JF Weel,, Wertheim-Van Dillen PM,, Berkhout RJ,, van Loon AM. 2005. Survey of acyclovir-resistant herpes simplex virus in the Netherlands: prevalence and characterization. J Clin Virol 32: 7– 18.
17. Duan R,, de Vries RD,, Osterhaus AD,, Remeijer L,, Verjans GM. 2008. Acyclovir-resistant corneal HSV-1 isolates from patients with herpetic keratitis. J Infect Dis 198: 659– 663.
18. Bestman-Smith J,, Boivin G. 2003. Drug resistance patterns of recombinant herpes simplex virus DNA polymerase mutants generated with a set of overlapping cosmids and plasmids. J Virol 77: 7820– 7829.
19. Nikkels AF,, Snoeck R,, Rentier B,, Pierard GE. 1999. Chronic verrucous varicella zoster virus skin lesions: clinical, histological, molecular and therapeutic aspects. Clin Exp Dermatol 24: 346– 353.
20. van der Beek MT,, Vermont CL,, Bredius RG,, Marijt EW,, van der Blij-de Brouwer CS,, Kroes AC,, Claas EC,, Vossen AC. 2013. Persistence and antiviral resistance of varicella zoster virus in hematological patients. Clin Infect Dis 56: 335– 343.
21. Andrei G,, Topalis D,, Fiten P,, McGuigan C,, Balzarini J,, Opdenakker G,, Snoeck R. 2012. In vitro-selected drug-resistant varicella-zoster virus mutants in the thymidine kinase and DNA polymerase genes yield novel phenotype-genotype associations and highlight differences between antiherpesvirus drugs. J Virol 86: 2641– 2652.
22. Morfin F,, Thouvenot D,, De Turenne-Tessier M,, Lina B,, Aymard M,, Ooka T. 1999. Phenotypic and genetic characterization of thymidine kinase from clinical strains of varicella-zoster virus resistant to acyclovir. Antimicrob Agents Chemother 43: 2412– 2416.
23. Sauerbrei A,, Taut J,, Zell R,, Wutzler P. 2011. Resistance testing of clinical varicella-zoster virus strains. Antiviral Res 90: 242– 247.
24. Hatchette T,, Tipples GA,, Peters G,, Alsuwaidi A,, Zhou J,, Mailman TL. 2008. Foscarnet salvage therapy for acyclovir-resistant varicella zoster: report of a novel thymidine kinase mutation and review of the literature. Pediatr Infect Dis J 27: 75– 77.
25. Bryan CJ,, Prichard MN,, Daily S,, Jefferson G,, Hartline C,, Cassady KA,, Hilliard L,, Shimamura M. 2008. Acyclovir-resistant chronic verrucous vaccine strain varicella in a patient with neuroblastoma. Pediatr Infect Dis J 27: 946– 948.
26. Prichard MN. 2009. Function of human cytomegalovirus UL97 kinase in viral infection and its inhibition by maribavir. Rev Med Virol 19: 215– 229.
27. Sullivan V,, Talarico CL,, Stanat SC,, Davis M,, Coen DM,, Biron KK. 1992. A protein kinase homologue controls phosphorylation of ganciclovir in human cytomegalovirus-infected cells. Nature 358: 162– 164.
28. Lurain NS,, Chou S. 2010. Antiviral drug resistance of human cytomegalovirus. Clin Microbiol Rev 23: 689– 712.
29. Kotton CN,, Kumar D,, Caliendo AM,, Asberg A,, Chou S,, Danziger-Isakov L,, Humar A. 2013. Updated international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation. Transplantation 96: 333– 360.
30. Chou S. 2010. Recombinant phenotyping of cytomegalovirus UL97 kinase sequence variants for ganciclovir resistance. Antimicrob Agents Chemother 54: 2371– 2378.
31. Chou S,, Marousek G,, Guentzel D,, Follansbee SE,, Poscher ME,, Lalezari JP,, Miner RC,, Drew WL. 1997. Evolution of mutations conferring multidrug resistance during prophylaxis and therapy for cytomegalovirus disease. J Infect Dis 176: 786– 789.
32. Chou S,, Van Wechel LC,, Lichy HM,, Marousek GI. 2005. Phenotyping of cytomegalovirus drug resistance mutations by using recombinant viruses incorporating a reporter gene. Antimicrob Agents Chemother 49: 2710– 2715.
33. Smith IL,, Cherrington JM,, Jiles RE,, Fuller MD,, Freeman WR,, Spector SA. 1997. High-level resistance of cytomegalovirus to ganciclovir is associated with alterations in both the UL97 and DNA polymerase genes. J Infect Dis 176: 69– 77.
34. Scott GM,, Weinberg A,, Rawlinson WD,, Chou S. 2007. Multidrug resistance conferred by novel DNA polymerase mutations in human cytomegalovirus isolates. Antimicrob Agents Chemother 51: 89– 94.
35. Baldanti F,, Underwood MR,, Stanat SC,, Biron KK,, Chou S,, Sarasini A,, Silini E,, Gerna G. 1996. Single amino acid changes in the DNA polymerase confer foscarnet resistance and slow-growth phenotype, while mutations in the UL97- encoded phosphotransferase confer ganciclovir resistance in three double-resistant human cytomegalovirus strains recovered from patients with AIDS. J Virol 70: 1390– 1395.
36. Chou S. 2011. Phenotypic diversity of cytomegalovirus DNA polymerase gene variants observed after antiviral therapy. J Clin Virol 50: 287– 291.
37. Chou S,, Marousek GI,, Van Wechel LC,, Li S,, Weinberg A. 2007. Growth and drug resistance phenotypes resulting from cytomegalovirus DNA polymerase region III mutations observed in clinical specimens. Antimicrob Agents Chemother 51: 4160– 4162.
38. Coffin JM. 1995. HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy. Science 267: 483– 489.
39. Frentz D,, Boucher CA,, van de Vijver DA. 2012. Temporal changes in the epidemiology of transmission of drug-resistant HIV-1 across the world. AIDS Rev 14: 17– 27.
40. Panel on Antiretroviral Guidelines for Adults and Adolescents. 2013. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. http://aidsinfo.nih.gov/contentfiles/lvguidelines/AdultandAdolescentGL.pdf.
41. Meyer PR,, Matsuura SE,, Schinazi RF,, So AG,, Scott WA. 2000. Differential removal of thymidine nucleotide analogues from blocked DNA chains by human immunodeficiency virus reverse transcriptase in the presence of physiological concentrations of 2′-deoxynucleoside triphosphates. Antimicrob Agents Chemother 44: 3465– 3472.
42. Whitcomb JM,, Parkin NT,, Chappey C,, Hellmann NS,, Petropoulos CJ. 2003. Broad nucleoside reverse-transcriptase inhibitor cross-resistance in human immunodeficiency virus type 1 clinical isolates. J Infect Dis 188: 992– 1000.
43. Singh K,, Marchand B,, Kirby KA,, Michailidis E,, Sarafianos SG. 2010. Structural aspects of drug resistance and inhibition of HIV-1 reverse transcriptase. Viruses 2: 606– 638.
44. Menéndez-Arias L. 2008. Mechanisms of resistance to nucleoside analogue inhibitors of HIV-1 reverse transcriptase. Virus Res 134: 124– 146.
45. Lanier ER,, Ait-Khaled M,, Scott J,, Stone C,, Melby T,, Sturge G,, St Clair M,, Steel H,, Hetherington S,, Pearce G,, Spreen W,, Lafon S. 2004. Antiviral efficacy of abacavir in antiretroviral therapy-experienced adults harbouring HIV-1 with specific patterns of resistance to nucleoside reverse transcriptase inhibitors. Antivir Ther 9: 37– 45.
46. Miller MD,, Margot N,, Lu B,, Zhong L,, Chen SS,, Cheng A,, Wulfsohn M. 2004. Genotypic and phenotypic predictors of the magnitude of response to tenofovir disoproxil fumarate treatment in antiretroviral-experienced patients. J Infect Dis 189: 837– 846.
47. Molina JM,, Marcelin AG,, Pavie J,, Heripret L,, De Boever CM,, Troccaz M,, Leleu G,, Calvez V. 2005. Didanosine in HIV-1-infected patients experiencing failure of antiretroviral therapy: a randomized placebo-controlled trial. J Infect Dis 191: 840– 847.
48. Tang MW,, Shafer RW. 2012. HIV-1 antiretroviral resistance: scientific principles and clinical applications. Drugs 72: e1– 25.
49. Parikh UM,, Koontz DL,, Chu CK,, Schinazi RF,, Mellors JW. 2005. In vitro activity of structurally diverse nucleoside analogs against human immunodeficiency virus type 1 with the K65R mutation in reverse transcriptase. Antimicrob Agents Chemother 49: 1139– 1144.
50. Melikian GL,, Rhee SY,, Taylor J,, Fessel WJ,, Kaufman D,, Towner W,, Troia-Cancio PV,, Zolopa A,, Robbins GK,, Kagan R,, Israelski D,, Shafer RW. 2012. Standardized comparison of the relative impacts of HIV-1 reverse transcriptase (RT) mutations on nucleoside RT inhibitor susceptibility. Antimicrob Agents Chemother 56: 2305– 2313.
51. Winters MA,, Coolley KL,, Girard YA,, Levee DJ,, Hamdan H,, Shafer RW,, Katzenstein DA,, Merigan TC. 1998. A 6-basepair insert in the reverse transcriptase gene of human immunodeficiency virus type 1 confers resistance to multiple nucleoside inhibitors. J Clin Invest 102: 1769– 1775.
52. Shafer RW,, Kozal MJ,, Winters MA,, Iversen AK,, Katzenstein DA,, Ragni MV,, Meyer WA,, Gupta P,, Rasheed S,, Coombs R,, Merigan TC. 1994. Combination therapy with zidovudine and didanosine selects for drug-resistant human immunodeficiency virus type 1 strains with unique patterns of pol gene mutations. J Infect Dis 169: 722– 729.
53. Shirasaka T,, Kavlick MF,, Ueno T,, Gao WY,, Kojima E,, Alcaide ML,, Chokekijchai S,, Roy BM,, Arnold E,, Yarchoan R,, Mitsuya H. 1995. Emergence of human immunodeficiency virus type 1 variants with resistance to multiple dideoxynucleosides in patients receiving therapy with dideoxynucleosides. Proc Natl Acad Sci U S A 92: 2398– 2402.
54. Menéndez-Arias L. 2013. Molecular basis of human immunodeficiency virus type 1 drug resistance: overview and recent developments. Antiviral Res 98: 93– 120.
55. Yang G,, Song Q,, Charles M,, Drosopoulos WC,, Arnold E,, Prasad VR. 1996. Use of chimeric human immunodeficiency virus types 1 and 2 reverse transcriptases for structure-function analysis and for mapping susceptibility to nonnucleoside inhibitors. J Acquir Immune Defic Syndr Hum Retrovirol 11: 326– 333.
56. Parkin NT,, Hellmann NS,, Whitcomb JM,, Kiss L,, Chappey C,, Petropoulos CJ. 2004. Natural variation of drug susceptibility in wild-type human immunodeficiency virus type 1. Antimicrob Agents Chemother 48: 437– 443.
57. Jackson JB,, Becker-Pergola G,, Guay LA,, Musoke P,, Mracna M,, Fowler MG,, Mofenson LM,, Mirochnick M,, Mmiro F,, Eshleman SH. 2000. Identification of the K103N resistance mutation in Ugandan women receiving nevirapine to prevent HIV-1 vertical transmission. AIDS 14: F111– F115.
58. Jourdain G,, Ngo-Giang-Huong N,, Le Coeur S,, Bowonwatanuwong C,, Kantipong P,, Leechanachai P,, Ariyadej S,, Leenasirimakul P,, Hammer S,, Lallemant M; Perinatal HIV Prevention Trial Group. 2004. Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy. N Engl J Med 351: 229– 240.
59. Vingerhoets J,, Tambuyzer L,, Azijn H,, Hoogstoel A,, Nijs S,, Peeters M,, de Bethune MP,, De Smedt G,, Woodfall B,, Picchio G. 2010. Resistance profile of etravirine: combined analysis of baseline genotypic and phenotypic data from the randomized, controlled phase III clinical studies. AIDS 24: 503– 514.
60. Das K,, Clark AD Jr,, Lewi PJ,, Heeres J,, De Jonge MR,, Koymans LM,, Vinkers HM,, Daeyaert F,, Ludovici DW,, Kukla MJ,, De Corte B,, Kavash RW,, Ho CY,, Ye H,, Lichtenstein MA,, Andries K,, Pauwels R,, De Bethune MP,, Boyer PL,, Clark P,, Hughes SH,, Janssen PA,, Arnold E. 2004. Roles of conformational and positional adaptability in structure-based design of TMC125-R165335 (etravirine) and related non-nucleoside reverse transcriptase inhibitors that are highly potent and effective against wild-type and drug-resistant HIV-1 variants. J Med Chem 47: 2550– 2560.
61. Melikian GL,, Rhee SY,, Varghese V,, Porter D,, White K,, Taylor J,, Towner W,, Troia P,, Burack J,, Dejesus E,, Robbins GK,, Razzeca K,, Kagan R,, Liu TF,, Fessel WJ,, Israelski D,, Shafer RW. 2014. Non-nucleoside reverse transcriptase inhibitor (NNRTI) cross-resistance: implications for preclinical evaluation of novel NNRTIs and clinical genotypic resistance testing. J Antimicrob Chemother 69: 12– 20.
62. Rimsky L,, Vingerhoets J,, Van Eygen V,, Eron J,, Clotet B,, Hoogstoel A,, Boven K,, Picchio G. 2012. Genotypic and phenotypic characterization of HIV-1 isolates obtained from patients on rilpivirine therapy experiencing virologic failure in the phase 3 ECHO and THRIVE studies: 48-week analysis. J Acquir Immune Defic Syndr 59: 39– 46.
63. Shahriar R,, Rhee SY,, Liu TF,, Fessel WJ,, Scarsella A,, Towner W,, Holmes SP,, Zolopa AR,, Shafer RW. 2009. Nonpolymorphic human immunodeficiency virus type 1 protease and reverse transcriptase treatment-selected mutations. Antimicrob Agents Chemother 53: 4869– 4878.
64. Rhee SY,, Taylor J,, Fessel WJ,, Kaufman D,, Towner W,, Troia P,, Ruane P,, Hellinger J,, Shirvani V,, Zolopa A,, Shafer RW. 2010. HIV-1 protease mutations and protease inhibitor cross-resistance. Antimicrob Agents Chemother 54: 4253– 4261.
65. Erickson JW,, Gulnik SV,, Markowitz M. 1999. Protease inhibitors: resistance, cross-resistance, fitness and the choice of initial and salvage therapies. AIDS 13( Suppl A) : S189– S204.
66. Ali A,, Bandaranayake RM,, Cai Y,, King NM,, Kolli M,, Mittal S,, Murzycki JF,, Nalam MN,, Nalivaika EA,, Ozen A,, Prabu-Jeyabalan MM,, Thayer K,, Schiffer CA. 2010. Molecular basis for drug resistance in HIV-1 protease. Viruses 2: 2509– 2535.
67. Fun A,, Wensing AM,, Verheyen J,, Nijhuis M. 2012. Human immunodeficiency virus gag and protease: partners in resistance. Retrovirology 9: 63.
68. King MS,, Rode R,, Cohen-Codar I,, Calvez V,, Marcelin AG,, Hanna GJ,, Kempf DJ. 2007. Predictive genotypic algorithm for virologic response to lopinavir-ritonavir in protease inhibitor-experienced patients. Antimicrob Agents Chemother 51: 3067– 3074.
69. de Meyer S,, Vangeneugden T,, van Baelen B,, de Paepe E,, van Marck H,, Picchio G,, Lefebvre E,, de Béthune MP. 2008. Resistance profile of darunavir: combined 24-week results from the POWER trials. AIDS Res Hum Retroviruses 24: 379– 388.
70. Bierman WF,, van Agtmael MA,, Nijhuis M,, Danner SA,, Boucher CA. 2009. HIV monotherapy with ritonavir-boosted protease inhibitors: a systematic review. AIDS 23: 279– 291.
71. Goldgur Y,, Craigie R,, Cohen GH,, Fujiwara T,, Yoshinaga T,, Fujishita T,, Sugimoto H,, Endo T,, Murai H,, Davies DR. 1999. Structure of the HIV-1 integrase catalytic domain complexed with an inhibitor: a platform for antiviral drug design. Proc Natl Acad Sci U S A 96: 13040– 13043.
72. Wang JY,, Ling H,, Yang W,, Craigie R. 2001. Structure of a two-domain fragment of HIV-1 integrase: implications for domain organization in the intact protein. EMBO J 20: 7333– 7343.
73. Chen X,, Tsiang M,, Yu F,, Hung M,, Jones GS,, Zeynalzadegan A,, Qi X,, Jin H,, Kim CU,, Swaminathan S,, Chen JM. 2008. Modeling, analysis, and validation of a novel HIV integrase structure provide insights into the binding modes of potent integrase inhibitors. J Mol Biol 380: 504– 519.
74. Hare S,, Gupta SS,, Valkov E,, Engelman A,, Cherepanov P. 2010. Retroviral intasome assembly and inhibition of DNA strand transfer. Nature 464: 232– 236.
75. Johnson AA,, Santos W,, Pais GC,, Marchand C,, Amin R,, Burke TR, Jr,, Verdine G,, Pommier Y. 2006. Integration requires a specific interaction of the donor DNA terminal 5′-cytosine with glutamine 148 of the HIV-1 integrase flexible loop. J Biol Chem 281: 461– 467.
76. McColl DJ,, Chen X. 2009. Strand transfer inhibitors of HIV-1 integrase: bringing IN a new era of antiretroviral therapy. Antiviral Res 85: 101– 118.
77. Fransen S,, Gupta S,, Frantzell A,, Petropoulos CJ,, Huang W. 2012. Substitutions at amino acid positions 143, 148, and 155 of HIV-1 integrase define distinct genetic barriers to raltegravir resistance in vivo. J Virol 86: 7249– 7255.
78. Hurt CB,, Sebastian J,, Hicks CB,, Eron JJ. 2014. Resistance to HIV integrase strand transfer inhibitors among clinical specimens in the United States, 2009–2012. Clin Infect Dis 58: 423– 431.
79. Blanco JL,, Varghese V,, Rhee SY,, Gatell JM,, Shafer RW. 2011. HIV-1 integrase inhibitor resistance and its clinical implications. J Infect Dis 203: 1204– 1214.
80. Abram ME,, Hluhanich RM,, Goodman DD,, Andreatta KN,, Margot NA,, Ye L,, Niedziela-Majka A,, Barnes TL,, Novikov N,, Chen X,, Svarovskaia ES,, McColl DJ,, White KL,, Miller MD. 2013. Impact of primary elvitegravir resistance-associated mutations in HIV-1 integrase on drug susceptibility and viral replication fitness. Antimicrob Agents Chemother 57: 2654– 2663.
81. Eron JJ,, Clotet B,, Durant J,, Katlama C,, Kumar P,, Lazzarin A,, Poizot-Martin I,, Richmond G,, Soriano V,, Ait-Khaled M,, Fujiwara T,, Huang J,, Min S,, Vavro C,, Yeo J, Viking Study Group. 2013. Safety and efficacy of dolutegravir in treatment-experienced subjects with raltegravir-resistant HIV type 1 infection: 24-week results of the VIKING Study. J Infect Dis 207: 740– 748.
82. Underwood MR,, Johns BA,, Sato A,, Martin JN,, Deeks SG,, Fujiwara T. 2012. The activity of the integrase inhibitor dolutegravir against HIV-1 variants isolated from raltegravir-treated adults. J Acquir Immune Defic Syndr 61: 297– 301.
83. Geretti AM,, Armenia D,, Ceccherini-Silberstein F. 2012. Emerging patterns and implications of HIV-1 integrase inhibitor resistance. Curr Opin Infect Dis 25: 677– 686.
84. Sista PR,, Melby T,, Davison D,, Jin L,, Mosier S,, Mink M,, Nelson EL,, DeMasi R,, Cammack N,, Salgo MP,, Matthews TJ,, Greenberg ML. 2004. Characterization of determinants of genotypic and phenotypic resistance to enfuvirtide in baseline and on-treatment HIV-1 isolates. AIDS 18: 1787– 1794.
85. Mink M,, Mosier SM,, Janumpalli S,, Davison D,, Jin L,, Melby T,, Sista P,, Erickson J,, Lambert D,, Stanfield-Oakley SA,, Salgo M,, Cammack N,, Matthews T,, Greenberg ML. 2005. Impact of human immunodeficiency virus type 1 gp41 amino acid substitutions selected during enfuvirtide treatment on gp41 binding and antiviral potency of enfuvirtide in vitro. J Virol 79: 12447– 12454.
86. Lu J,, Deeks SG,, Hoh R,, Beatty G,, Kuritzkes BA,, Martin JN,, Kuritzkes DR. 2006. Rapid emergence of enfuvirtide resistance in HIV-1-infected patients: results of a clonal analysis. J Acquir Immune Defic Syndr 43: 60– 64.
87. Tan Q,, Zhu Y,, Li J,, Chen Z,, Han GW,, Kufareva I,, Li T,, Ma L,, Fenalti G,, Li J,, Zhang W,, Xie X,, Yang H,, Jiang H,, Cherezov V,, Liu H,, Stevens RC,, Zhao Q,, Wu B. 2013. Structure of the CCR5 chemokine receptor-HIV entry inhibitor maraviroc complex. Science 341: 1387– 1390.
88. Westby M,, Lewis M,, Whitcomb J,, Youle M,, Pozniak AL,, James IT,, Jenkins TM,, Perros M,, van der Ryst E. 2006. Emergence of CXCR4-using human immunodeficiency virus type 1 (HIV-1) variants in a minority of HIV-1-infected patients following treatment with the CCR5 antagonist maraviroc is from a pretreatment CXCR4-using virus reservoir. J Virol 80: 4909– 4920.
89. Hartley O,, Klasse PJ,, Sattentau QJ,, Moore JP. 2005. V3: HIV’s switch hitter. AIDS Res Hum Retroviruses 21: 171– 189.
90. Westby M,, Smith-Burchnell C,, Mori J,, Lewis M,, Mosley M,, Stockdale M,, Dorr P,, Ciaramella G,, Perros M. 2007. Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entry. J Virol 81: 2359– 2371.
91. Tebit DM,, Arts EJ. 2011. Tracking a century of global expansion and evolution of HIV to drive understanding and to combat disease. Lancet Infect Dis 11: 45– 56.
92. Bennett DE,, Camacho RJ,, Otelea D,, Kuritzkes DR,, Fleury H,, Kiuchi M,, Heneine W,, Kantor R,, Jordan MR,, Schapiro JM,, Vandamme AM,, Sandstrom P,, Boucher CA,, van de Vijver D,, Rhee SY,, Liu TF,, Pillay D,, Shafer RW. 2009. Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update. PLoS One 4: e4724. doi:10.1371/journal.pone.0004724
93. Hamers RL,, Sigaloff KC,, Wensing AM,, Wallis CL,, Kityo C,, Siwale M,, Mandaliya K,, Ive P,, Botes ME,, Wellington M,, Osibogun A,, Stevens WS,, Rinke de Wit TF,, Schuurman R, PharmAccess African Studies to Evaluate Resistance (PASER). 2012. Patterns of HIV-1 drug resistance after first-line antiretroviral therapy (ART) failure in 6 sub-Saharan African countries: implications for second-line ART strategies. Clin Infect Dis 54: 1660– 1669.
94. Werle-Lapostolle B,, Bowden S,, Locarnini S,, Wursthorn K,, Petersen J,, Lau G,, Trepo C,, Marcellin P,, Goodman Z,, Delaney WE IV,, Xiong S,, Brosgart CL,, Chen SS,, Gibbs CS,, Zoulim F. 2004. Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. Gastroenterology 126: 1750– 1758.
95. Wong DK,, Seto WK,, Fung J,, Ip P,, Huang FY,, Lai CL,, Yuen MF. 2013. Reduction of hepatitis B surface antigen and covalently closed circular DNA by nucleos(t)ide analogues of different potency. Clin Gastroenterol Hepatol 11: 1004– 1010.e1.
96. Nowak MA,, Bonhoeffer S,, Hill AM,, Boehme R,, Thomas HC,, McDade H. 1996. Viral dynamics in hepatitis B virus infection. Proc Natl Acad Sci U S A 93: 4398– 4402.
97. Hollinger FB. 2007. Hepatitis B virus genetic diversity and its impact on diagnostic assays. J Viral Hepat 14( Suppl 1) : 11– 15.
98. Zaaijer HL,, van Hemert FJ,, Koppelman MH,, Lukashov VV. 2007. Independent evolution of overlapping polymerase and surface protein genes of hepatitis B virus. J Gen Virol 88: 2137– 2143.
99. Soriano V,, Perelson AS,, Zoulim F. 2008. Why are there different dynamics in the selection of drug resistance in HIV and hepatitis B and C viruses? J Antimicrob Chemother 62: 1– 4.
100. Fung SK,, Lok AS. 2004. Hepatitis B virus genotypes: do they play a role in the outcome of HBV infection? Hepatology 40: 790– 792.
101. Moucari R,, Martinot-Peignoux M,, Mackiewicz V,, Boyer N,, Ripault MP,, Castelnau C,, Leclere L,, Dauvergne A,, Valla D,, Vidaud M,, Nicolas-Chanoine MH,, Marcellin P. 2009. Influence of genotype on hepatitis B surface antigen kinetics in hepatitis B e antigen-negative patients treated with pegylated interferon-alpha2a. Antivir Ther 14: 1183– 1188.
102. Stuyver LJ,, Locarnini SA,, Lok A,, Richman DD,, Carman WF,, Dienstag JL,, Schinazi RF. 2001. Nomenclature for antiviral-resistant human hepatitis B virus mutations in the polymerase region. Hepatology 33: 751– 757.
103. European Association For The Study Of The Liver. 2012. EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol 57: 167– 185.
104. Tenney DJ,, Rose RE,, Baldick CJ,, Pokornowski KA,, Eggers BJ,, Fang J,, Wichroski MJ,, Xu D,, Yang J,, Wilber RB,, Colonno RJ. 2009. Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5 years of therapy. Hepatology 49: 1503– 1514.
105. Kitrinos KM,, Corsa A,, Liu Y,, Flaherty J,, Snow-Lampart A,, Marcellin P,, Borroto-Esoda K,, Miller MD. 2014. No detectable resistance to tenofovir disoproxil fumarate after 6 years of therapy in patients with chronic hepatitis B. Hepatology 59: 434– 442.
106. Lai CL,, Dienstag J,, Schiff E,, Leung NW,, Atkins M,, Hunt C,, Brown N,, Woessner M,, Boehme R,, Condreay L. 2003. Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. Clin Infect Dis 36: 687– 696.
107. Liaw YF,, Gane E,, Leung N,, Zeuzem S,, Wang Y,, Lai CL,, Heathcote EJ,, Manns M,, Bzowej N,, Niu J,, Han SH,, Hwang SG,, Cakaloglu Y,, Tong MJ,, Papatheodoridis G,, Chen Y,, Brown NA,, Albanis E,, Galil K,, Naoumov NV, GLOBE Study Group. 2009. 2-Year GLOBE trial results: telbivudine Is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology 136: 486– 495.
108. Hadziyannis SJ,, Tassopoulos NC,, Heathcote EJ,, Chang TT,, Kitis G,, Rizzetto M,, Marcellin P,, Lim SG,, Goodman Z,, Ma J,, Brosgart CL,, Borroto-Esoda K,, Arterburn S,, Chuck SL, Adefovir Dipivoxil 438 Study Group. 2006. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology 131: 1743– 1751.
109. Das K,, Xiong ,, Yang H,, Westland CE,, Gibbs CS,, Sarafianos SG,, Arnold E. 2001. Molecular modeling and biochemical characterization reveal the mechanism of hepatitis B virus polymerase resistance to lamivudine (3TC) and emtricitabine (FTC). J Virol 75: 4771– 4779.
110. Bartholomeusz A,, Tehan BG,, Chalmers DK. 2004. Comparisons of the HBV and HIV polymerase, and antiviral resistance mutations. Antivir Ther 9: 149– 160.
111. Lok AS,, Zoulim F,, Locarnini S,, Bartholomeusz A,, Ghany MG,, Pawlotsky JM,, Liaw YF,, Mizokami M,, Kuiken C, Hepatitis B Virus Drug Resistance Working Group. 2007. Antiviral drug-resistant HBV: standardization of nomenclature and assays and recommendations for management. Hepatology 46: 254– 265.
112. Devi U,, Locarnini S. 2013. Hepatitis B antivirals and resistance. Curr Opin Virol 3: 495– 500.
113. Liaw YF,, Chien RN,, Yeh CT. 2004. No benefit to continue lamivudine therapy after emergence of YMDD mutations. Antivir Ther 9: 257– 262.
114. Di Marco V,, Di Stefano R,, Ferraro D,, Almasio PL,, Bonura C,, Giglio M,, Parisi P,, Cappello M,, Alaimo G,, Craxi A. 2005. HBV-DNA suppression and disease course in HBV cirrhosis patients on long-term lamivudine therapy. Antivir Ther 10: 431– 439.
115. Peters MG,, Hann Hw,, Martin P,, Heathcote EJ,, Buggisch P,, Rubin R,, Bourliere M,, Kowdley K,, Trepo C,, Gray Df,, Sullivan M,, Kleber K,, Ebrahimi R,, Xiong S,, Brosgart CL. 2004. Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology 126: 91– 101.
116. Westland CE,, Yang H,, Delaney WE IV,, Wulfsohn M,, Lama N,, Gibbs CS,, Miller MD,, Fry J,, Brosgart CL,, Schiff ER,, Xiong S. 2005. Activity of adefovir dipivoxil against all patterns of lamivudine-resistant hepatitis B viruses in patients. J Viral Hepat 12: 67– 73.
117. Fung SK,, Chae HB,, Fontana RJ,, Conjeevaram H,, Marrero J,, Oberhelman K,, Hussain M,, Lok AS. 2006. Virologic response and resistance to adefovir in patients with chronic hepatitis B. J Hepatol 44: 283– 290.
118. Borroto-Esoda K,, Miller MD,, Arterburn S. 2007. Pooled analysis of amino acid changes in the HBV polymerase in patients from four major adefovir dipivoxil clinical trials. J Hepatol 47: 492– 498.
119. Santantonio T,, Fasano M,, Durantel S,, Barraud L,, Heichen M,, Guastadisegni A,, Pastore G,, Zoulim F. 2009. Adefovir dipivoxil resistance patterns in patients with lamivudine-resistant chronic hepatitis B. Antivir Ther 14: 557– 565.
120. Yang H,, Westland C,, Xiong S,, Delaney WE IV. 2004. In vitro antiviral susceptibility of full-length clinical hepatitis B virus isolates cloned with a novel expression vector. Antiviral Res 61: 27– 36.
121. Zoulim F,, Locarnini S. 2013. Optimal management of chronic hepatitis B patients with treatment failure and antiviral drug resistance. Liver Int 33( Suppl 1) : 116– 124.
122. Yatsuji H,, Noguchi C,, Hiraga N,, Mori N,, Tsuge M,, Imamura M,, Takahashi S,, Iwao E,, Fujimoto Y,, Ochi H,, Abe H,, Maekawa T,, Tateno C,, Yoshizato K,, Suzuki F,, Kumada H,, Chayama K. 2006. Emergence of a novel lamivudine-resistant hepatitis B virus variant with a substitution outside the YMDD motif. Antimicrob Agents Chemother 50: 3867– 3874.
123. Villet S,, Pichoud C,, Billioud G,, Barraud L,, Durantel S,, Trépo C,, Zoulim F. 2008. Impact of hepatitis B virus rtA181V/T mutants on hepatitis B treatment failure. J Hepatol 48: 747– 755.
124. Warner N,, Locarnini S. 2008. The antiviral drug selected hepatitis B virus rtA181T/sW172* mutant has a dominant negative secretion defect and alters the typical profile of viral rebound. Hepatology 48: 88– 98.
125. Tenney DJ,, Rose RE,, Baldick CJ,, Levine SM,, Pokornowski KA,, Walsh AW,, Fang J,, Yu CF,, Zhang S,, Mazzucco CE,, Eggers B,, Hsu M,, Plym MJ,, Poundstone P,, Yang J,, Colonno RJ. 2007. Two-year assessment of entecavir resistance in Lamivudine-refractory hepatitis B virus patients reveals different clinical outcomes depending on the resistance substitutions present. Antimicrob Agents Chemother 51: 902– 911.
126. Sherman M,, Yurdaydin C,, Simsek H,, Silva M,, Liaw YF,, Rustgi VK,, Sette H,, Tsai N,, Tenney DJ,, Vaughan J,, Kreter B,, Hindes R, AI463026 Benefits of Entecavir for Hepatitis B Liver Disease (BEHOLD) Study Group. 2008. Entecavir therapy for lamivudine-refractory chronic hepatitis B: improved virologic, biochemical, and serology outcomes through 96 weeks. Hepatology 48: 99– 108.
127. Koffi J,, Egounlety R,, Pradat P,, Lebosse F,, Si-Ahmed SN,, Lussier V,, Chevallier P,, Bailly F,, Zoulim F. 2014. Impact of lamivudine-resistance mutations on entecavir treatment outcome in hepatitis B. Eur J Gastroenterol Hepatol 26: 146– 154.
128. Tenney DJ,, Levine SM,, Rose RE,, Walsh AW,, Weinheimer SP,, Discotto L,, Plym M,, Pokornowski K,, Yu CF,, Angus P,, Ayres A,, Bartholomeusz A,, Sievert W,, Thompson G,, Warner N,, Locarnini S,, Colonno RJ. 2004. Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to lamivudine. Antimicrob Agents Chemother 48: 3498– 3507.
129. van Bömmel F,, de Man RA,, Wedemeyer H,, Deterding K,, Petersen J,, Buggisch P,, Erhardt A,, Hüppe D,, Stein K,, Trojan J,, Sarrazin C,, Böcher WO,, Spengler U,, Wasmuth HE,, Reinders JG,, Möller B,, Rhode P,, Feucht HH,, Wiedenmann B,, Berg T. 2010. Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside/nucleotide analogues. Hepatology 51: 73– 80.
130. Schildgen O,, Sirma H,, Funk A,, Olotu C,, Wend UC,, Hartmann H,, Helm M,, Rockstroh JK,, Willems WR,, Will H,, Gerlich WH. 2006. Variant of hepatitis B virus with primary resistance to adefovir. N Engl J Med 354: 1807– 1812.
131. Sheldon J,, Camino N,, Rodés B,, Bartholomeusz A,, Kuiper M,, Tacke F,, Nuñez M,, Mauss S,, Lutz T,, Klausen G,, Locarnini S,, Soriano V. 2005. Selection of hepatitis B virus polymerase mutations in HIV-coinfected patients treated with tenofovir. Antivir Ther 10: 727– 734.
132. Rhee SY,, Margeridon-Thermet S,, Nguyen MH,, Liu TF,, Kagan RM,, Beggel B,, Verheyen J,, Kaiser R,, Shafer RW. 2010. Hepatitis B virus reverse transcriptase sequence variant database for sequence analysis and mutation discovery. Antiviral Res 88: 269– 275.
133. Qi X,, Xiong S,, Yang H,, Miller M,, Delaney WE IV. 2007. In vitro susceptibility of adefovir-associated hepatitis B virus polymerase mutations to other antiviral agents. Antivir Ther 12: 355– 362.
134. Bartenschlager R,, Lohmann V,, Penin F. 2013. The molecular and structural basis of advanced antiviral therapy for hepatitis C virus infection. Nature Rev Microbiol 11: 482– 496.
135. Herrmann E,, Neumann AU,, Schmidt JM,, Zeuzem S. 2000. Hepatitis C virus kinetics. Antivir Ther 5: 85– 90.
136. Powdrill MH,, Tchesnokov EP,, Kozak RA,, Russell RS,, Martin R,, Svarovskaia ES,, Mo H,, Kouyos RD,, Gotte M. 2011. Contribution of a mutational bias in hepatitis C virus replication to the genetic barrier in the development of drug resistance. Proc Natl Acad Sci U S A 108: 20509– 20513.
137. Smith DB,, Bukh J,, Kuiken C,, Muerhoff AS,, Rice CM,, Stapleton JT,, Simmonds P. 2014. Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: updated criteria and assignment web resource. Hepatology 59: 318– 327.
138. Fan X,, Mao Q,, Zhou D,, Lu Y,, Xing J,, Xu Y,, Ray SC,, Di Bisceglie AM. 2009. High diversity of hepatitis C viral quasispecies is associated with early virological response in patients undergoing antiviral therapy. Hepatology 50: 1765– 1772.
139. Lemon SM. 2010. Induction and evasion of innate antiviral responses by hepatitis C virus. J Biol Chem 285: 22741– 22747.
140. Food and Drug Administration. 2013. Olysio (simeprevir): prescribing information. http://www.accessdata .fda.gov/drugsatfda_docs/label/2013/205123s001lbl.pdf
141. Food and Drug Administration. 2013. Sovaldi (sofusbuvir): prescribing information. https://www.gilead.com/~/media/Files/pdfs/medicines/liver-disease/sovaldi/sovaldi_pi.pdf
142. Janssen HL,, Reesink HW,, Lawitz EJ,, Zeuzem S,, Rodriguez-Torres M,, Patel K,, van der Meer AJ,, Patick AK,, Chen A,, Zhou Y,, Persson R,, King BD,, Kauppinen S,, Levin AA,, Hodges MR. 2013. Treatment of HCV infection by targeting microRNA. N Engl J Med 368: 1685– 1694.
143. Flisiak R,, Jaroszewicz J,, Flisiak I,, Lapinski T. 2012. Update on alisporivir in treatment of viral hepatitis C. Expert Opin Investig Drugs 21: 375– 382.
144. Gane EJ,, Stedman CA,, Hyland RH,, Ding X,, Svarovskaia E,, Symonds WT,, Hindes RG,, Berrey MM. 2013. Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N Engl J Med 368: 34– 44.
145. Zeuzem S,, Soriano V,, Asselah T,, Bronowicki JP,, Lohse AW,, Müllhaupt B,, Schuchmann M,, Bourlière M,, Buti M,, Roberts SK,, Gane EJ,, Stern JO,, Vinisko R,, Kukolj G,, Gallivan JP,, Böcher WO,, Mensa FJ. 2013. Faldaprevir and deleobuvir for HCV genotype 1 infection. N Engl J Med 369: 630– 639.
146. Lawitz E,, Poordad FF,, Pang PS,, Hyland RH,, Ding X,, Mo H,, Symonds WT,, McHutchison JG,, Membreno FE. 2014. Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial. Lancet 383: 515– 523.
147. Poordad F,, Lawitz E,, Kowdley KV,, Cohen DE,, Podsadecki T,, Siggelkow S,, Heckaman M,, Larsen L,, Menon R,, Koev ,, Tripathi R,, Pilot-Matias T,, Bernstein B. 2013. Exploratory study of oral combination antiviral therapy for hepatitis C. N Engl J Med 368: 45– 53.
148. McCown MF,, Rajyaguru S,, Le Pogam S,, Ali S,, Jiang WR,, Kang H,, Symons J,, Cammack N,, Najera I. 2008. The hepatitis C virus replicon presents a higher barrier to resistance to nucleoside analogs than to nonnucleoside polymerase or protease inhibitors. Antimicrob Agents Chemother 52: 1604– 1612.
149. Foster GR,, Hézode C,, Bronowicki JP,, Carosi G,, Weiland O,, Verlinden L,, van Heeswijk R,, van Baelen B,, Picchio G,, Beumont M. 2011. Telaprevir alone or with peginterferon and ribavirin reduces HCV RNA in patients with chronic genotype 2 but not genotype 3 infections. Gastroenterology 141: 881– 889 e1.
150. Lenz O,, Vijgen L,, Berke JM,, Cummings MD,, Fevery B,, Peeters M,, De Smedt G,, Moreno C,, Picchio G. 2013. Virologic response and characterisation of HCV genotype 2-6 in patients receiving TMC435 monotherapy (study TMC435-C202). J Hepatol 58: 445– 451.
151. Lohmann V,, Bartenschlager R. 2013. On the history of hepatitis C virus cell culture systems. J Med Chem 47: 13967– 13975.
152. Kwong AD,, Najera I,, Bechtel J,, Bowden S,, Fitzgibbon J,, Harrington P,, Kempf D,, Kieffer TL,, Koletzki D,, Kukolj G,, Lim S,, Pilot-Matias T,, Lin K,, Mani N,, Mo H,, O’Rear J,, Otto M,, Parkin N,, Pawlotsky JM,, Petropoulos C,, Picchio G,, Ralston R,, Reeves JD,, Schooley RT,, Seiwert S,, Standring D,, Stuyver L,, Sullivan J,, Miller V, Forum for Collaborative Human Immunodeficiency Virus Research, HCV Drug Development Advisory Group (HCV DRAG), Sequence Analysis Working Group (SAWG), Phenotype Analysis Working Group (PAWG). 2011. Sequence and phenotypic analysis for resistance monitoring in hepatitis C virus drug development: recommendations from the HCV DRAG. Gastroenterology 140: 755– 760.
153. Cannon NA,, Donlin MJ,, Fan X,, Aurora R,, Tavis JE,, Virahep-C Study Group. 2008. Hepatitis C virus diversity and evolution in the full open-reading frame during antiviral therapy. PLoS One 3: e2123. doi:10.1371/journal .pone.1002832
154. Cuevas JM,, Torres-Puente M,, Jiménez-Hernández N,, Bracho MA,, García-Robles I,, Wrobel B,, Carnicer F,, del Olmo J,, Ortega E,, Moya A,, González-Candelas F. 2008. Genetic variability of hepatitis C virus before and after combined therapy of interferon plus ribavirin. PLoS One 3: e3058. doi:10.1371/journal.pone.0003058
155. Romano KP,, Ali A,, Aydin C,, Soumana D,, Ozen A,, Deveau LM,, Silver C,, Cao H,, Newton A,, Petropoulos CJ,, Huang W,, Schiffer CA. 2012. The molecular basis of drug resistance against hepatitis C virus NS3/4A protease inhibitors. PLoS Pathog 8: e1002832. doi:10.1371/journal .ppat.1002832
156. Kwong AD,, Kim JL,, Rao G,, Lipovsek D,, Raybuck SA. 1999. Hepatitis C virus NS3/4A protease. Antiviral Res 41: 67– 84.
157. Lenz O,, Verbinnen T,, Lin TI,, Vijgen L,, Cummings MD,, Lindberg J,, Berke JM,, Dehertogh P,, Fransen E,, Scholliers A,, Vermeiren K,, Ivens T,, Raboisson P,, Edlund M,, Storm S,, Vrang L,, de Kock H,, Fanning GC,, Simmen KA. 2010. In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435. Antimicrob Agents Chemother 54: 1878– 1887.
158. Sarrazin C,, Zeuzem S. 2010. Resistance to direct antiviral agents in patients with hepatitis C virus infection. Gastroenterology 138: 447– 462.
159. Halfon P,, Locarnini S. 2011. Hepatitis C virus resistance to protease inhibitors. J Hepatol 55: 192– 206.
160. Sullivan JC,, De Meyer S,, Bartels DJ,, Dierynck I,, Zhang EZ,, Spanks J,, Tigges AM,, Ghys A,, Dorrian J,, Adda N,, Martin EC,, Beumont M,, Jacobson IM,, Sherman KE,, Zeuzem S,, Picchio G,, Kieffer TL. 2013. Evolution of treatment-emergent resistant variants in telaprevir phase 3 clinical trials. Clin Infect Dis 57: 221– 229.
161. Perry CM. 2012. Telaprevir: a review of its use in the management of genotype 1 chronic hepatitis C. Drugs 72: 619– 641.
162. HCV Phenotype Working Group - HCV Drug Development Advisory Group. 2012. Clinically relevant HCV drug resistance mutations. Ann Form Collab HIV Res 14: 1– 10.
163. Susser S,, Vermehren J,, Forestier N,, Welker MW,, Grigorian N,, Fuller C,, Perner D,, Zeuzem S,, Sarrazin C. 2011. Analysis of long-term persistence of resistance mutations within the hepatitis C virus NS3 protease after treatment with telaprevir or boceprevir. J Clin Virol 52: 321– 327.
164. Bae A,, Sun SC,, Qi X,, Chen X,, Ku K,, Worth A,, Wong KA,, Harris J,, Miller MD,, Mo H. 2010. Susceptibility of treatment-naive hepatitis C virus (HCV) clinical isolates to HCV protease inhibitors. Antimicrob Agents Chemother 54: 5288– 5297.
165. Mosley RT,, Edwards TE,, Murakami E,, Lam AM,, Grice RL,, Du J,, Sofia MJ,, Furman PA,, Otto MJ. 2012. Structure of hepatitis C virus polymerase in complex with primer-template RNA. J Virol 86: 6503– 6511.
166. Caillet-Saguy C,, Simister PC,, Bressanelli S. 2011. An objective assessment of conformational variability in complexes of hepatitis C virus polymerase with non-nucleoside inhibitors. J Mol Biol 414: 370– 384.
167. Sofia MJ,, Chang W,, Furman PA,, Mosley RT,, Ross BS. 2012. Nucleoside, nucleotide, and non-nucleoside inhibitors of hepatitis C virus NS5B RNA-dependent RNA-polymerase. J Med Chem 55: 2481– 2531.
168. Lam AM,, Espiritu C,, Bansal S,, Micolochick Steuer HM,, Niu C,, Zennou V,, Keilman M,, Zhu Y,, Lan S,, Otto MJ,, Furman PA. 2012. Genotype and subtype profiling of PSI-7977 as a nucleotide inhibitor of hepatitis C virus. Antimicrob Agents Chemother 56: 3359– 3368.
169. Tong X,, Le Pogam S,, Li L,, Haines K,, Piso K,, Baronas V,, Yan JM,, So SS,, Klumpp K,, Nájera I. 2014. In vivo emergence of a novel mutant L159F/L320F in the NS5B polymerase confers low-level resistance to the HCV polymerase inhibitors mericitabine and sofosbuvir. J Infect Dis 209: 668– 675.
170. Migliaccio G,, Tomassini JE,, Carroll SS,, Tomei L,, Altamura S,, Bhat B,, Bartholomew L,, Bosserman MR,, Ceccacci A,, Colwell LF,, Cortese R,, De Francesco R,, Eldrup AB,, Getty KL,, Hou XS,, LaFemina RL,, Ludmerer SW,, MacCoss M,, McMasters DR,, Stahlhut MW,, Olsen DB,, Hazuda DJ,, Flores OA. 2003. Characterization of resistance to non-obligate chain-terminating ribonucleoside analogs that inhibit hepatitis C virus replication in vitro. J Biol Chem 278: 49164– 49170.
171. Najera I. 2013. Resistance to HCV nucleoside analogue inhibitors of hepatitis C virus RNA-dependent RNA polymerase. Curr Opin Virol 3: 508– 513.
172. Pauwels F,, Mostmans W,, Quirynen LM,, van der Helm L,, Boutton CW,, Rueff AS,, Cleiren E,, Raboisson P,, Surleraux D,, Nyanguile O,, Simmen KA. 2007. Binding-site identification and genotypic profiling of hepatitis C virus polymerase inhibitors. J Virol 81: 6909– 6919.
173. Hang JQ,, Yang Y,, Harris SF,, Leveque V,, Whittington HJ,, Rajyaguru S,, Ao-Ieong G,, McCown MF,, Wong A,, Giannetti AM,, Le Pogam S,, Talamás F,, Cammack N,, Nájera I,, Klumpp K. 2009. Slow binding inhibition and mechanism of resistance of non-nucleoside polymerase inhibitors of hepatitis C virus. J Biol Chem 284: 15517– 15529.
174. Aloia AL,, Locarnini S,, Beard MR. 2012. Antiviral resistance and direct-acting antiviral agents for HCV. Antivir Ther 17: 1147– 1162.
175. Kukolj G,, McGibbon GA,, McKercher G,, Marquis M,, Lefebvre S,, Thauvette L,, Gauthier J,, Goulet S,, Poupart MA,, Beaulieu PL. 2005. Binding site characterization and resistance to a class of non-nucleoside inhibitors of the hepatitis C virus NS5B polymerase. J Biol Chem 280: 39260– 39267.
176. Kuntzen T,, Timm J,, Berical A,, Lennon N,, Berlin AM,, Young SK,, Lee B,, Heckerman D,, Carlson J,, Reyor LL,, Kleyman M,, McMahon CM,, Birch C,, Schulze Zur Wiesch J,, Ledlie T,, Koehrsen M,, Kodira C,, Roberts AD,, Lauer GM,, Rosen HR,, Bihl F,, Cerny A,, Spengler U,, Liu Z,, Kim AY,, Xing Y,, Schneidewind A,, Madey MA,, Fleckenstein JF,, Park VM,, Galagan JE,, Nusbaum C,, Walker BD,, Lake-Bakaar GV,, Daar ES,, Jacobson IM,, Gomperts ED,, Edlin BR,, Donfield SM,, Chung RT,, Talal AH,, Marion T,, Birren BW,, Henn MR,, Allen TM. 2008. Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naive patients. Hepatology 48: 1769– 1778.
177. Gaudieri S,, Rauch A,, Pfafferott K,, Barnes E,, Cheng W,, McCaughan G,, Shackel N,, Jeffrey GP,, Mollison L,, Baker R,, Furrer H,, Gunthard HF,, Freitas E,, Humphreys I,, Klenerman P,, Mallal S,, James I,, Roberts S,, Nolan D,, Lucas M. 2009. Hepatitis C virus drug resistance and immune-driven adaptations: relevance to new antiviral therapy. Hepatology 49: 1069– 1082.
178. Gao M,, Nettles RE,, Belema M,, Snyder LB,, Nguyen VN,, Fridell RA,, Serrano-Wu MH,, Langley DR,, Sun JH,, O’Boyle DR, II,, Lemm JA,, Wang C,, Knipe JO,, Chien C,, Colonno RJ,, Grasela DM,, Meanwell NA,, Hamann LG. 2010. Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect. Nature 465: 96– 100.
179. Gao M. 2013. Antiviral activity and resistance of HCV NS5A replication complex inhibitors. Curr Opin Virol 3: 514– 520.
180. Everson GT,, Sims KD,, Rodriguez-Torres M,, Hézode C,, Lawitz E,, Bourlière M,, Loustaud-Ratti V,, Rustgi V,, Schwartz H,, Tatum H,, Marcellin P,, Pol S,, Thuluvath PJ,, Eley T,, Wang X,, Huang SP,, McPhee F,, Wind-Rotolo M,, Chung E,, Pasquinelli C,, Grasela DM,, Gardiner DF. 2014. Efficacy of an interferon- and ribavirin-free regimen of daclatasvir, asunaprevir, and BMS-791325 in treatment-naive patients with HCV genotype 1 infection. Gastroenterology 146: 420– 429.
181. Hernandez D,, Zhou N,, Ueland J,, Monikowski A,, McPhee F. 2013. Natural prevalence of NS5A polymorphisms in subjects infected with hepatitis C virus genotype 3 and their effects on the antiviral activity of NS5A inhibitors. J Clin Virol 57: 13– 18.
182. Novel Swine-Origin Influenza, A Virus Investigation Team, Dawood FS,, Jain S,, Finelli L,, Shaw MW,, Lindstrom S,, Garten RJ,, Gubareva LV,, Xu X,, Bridges CB,, Uyeki TM. 2009. Emergence of a novel swine-origin influenza A (H1N1) virus in humans. N Engl J Med 360: 2605– 2615.
183. Writing Committee of the Second World Health Organization Consultation on Clinical Aspects of Human Infection with Avian Influenza (HFN1) Virus, Abdel-Ghafar AN,, Chotpitayasunondh T,, Gao Z,, Hayden FG,, Nguyen DH,, de Jong MD,, Naghdaliyev A,, Peiris JS,, Shindo N,, Soeroso S,, Uyeki TM. 2008. Update on avian influenza A (H5N1) virus infection in humans. N Engl J Med 358: 261– 273.
184. To KK,, Chan JF,, Chen H,, Li L,, Yuen KY. 2013. The emergence of influenza A H7N9 in human beings 16 years after influenza A H5N1: a tale of two cities. Lancet Infect Dis 13: 809– 821.
185. Burnham AJ,, Baranovich T,, Govorkova EA. 2013. Neuraminidase inhibitors for influenza B virus infection: efficacy and resistance. Antiviral Res 100: 520– 534.
186. Härter G,, Zimmermann O,, Maier L,, Schubert A,, Mertens T,, Kern P,, Wöhrle J. 2010. Intravenous zanamivir for patients with pneumonitis due to pandemic (H1N1) 2009 influenza virus. Clin Infect Dis 50: 1249– 1251.
187. Hayden FG. 2013. Newer influenza antivirals, biotherapeutics and combinations. Influenza Other Respir Viruses 7( Suppl 1): 63– 75.
188. Cady SD,, Luo W,, Hu F,, Hong M. 2009. Structure and function of the influenza A M2 proton channel. Biochemistry 48: 7356– 7364.
189. Pielak RM,, Schnell JR,, Chou JJ. 2009. Mechanism of drug inhibition and drug resistance of influenza A M2 channel. Proc Natl Acad Sci U S A 106: 7379– 7384.
190. Belshe RB,, Burk B,, Newman F,, Cerruti RL,, Sim IS. 1989. Resistance of influenza A virus to amantadine and rimantadine: results of one decade of surveillance. J Infect Dis 159: 430– 435.
191. Wang J,, Qiu JX,, Soto C,, DeGrado WF. 2011. Structural and dynamic mechanisms for the function and inhibition of the M2 proton channel from influenza A virus. Curr Opin Struct Biol 21: 68– 80.
192. Hayden FG,, Hay AJ. 1992. Emergence and transmission of influenza A viruses resistant to amantadine and rimantadine. Curr Top Microbiol Immunol 176: 119– 130.
193. Shiraishi K,, Mitamura K,, Sakai-Tagawa Y,, Goto H,, Sugaya N,, Kawaoka Y. 2003. High frequency of resistant viruses harboring different mutations in amantadine-treated children with influenza. J Infect Dis 188: 57– 61.
194. Bright RA,, Shay DK,, Shu B,, Cox NJ,, Klimov AI. 2006. Adamantane resistance among influenza A viruses isolated early during the 2005–2006 influenza season in the United States. JAMA 295: 891– 894.
195. Smith BJ,, McKimm-Breshkin JL,, McDonald M,, Fernley RT,, Varghese JN,, Colman PM. 2002. Structural studies of the resistance of influenza virus neuramindase to inhibitors. J Med Chem 45: 2207– 2212.
196. Wagner R,, Matrosovich M,, Klenk HD. 2002. Functional balance between haemagglutinin and neuraminidase in influenza virus infections. Rev Med Virol 12: 159– 166.
197. Okomo-Adhiambo M,, Sleeman K,, Lysén C,, Nguyen HT,, Xu X,, Li Y,, Klimov AI,, Gubareva LV. 2013. Neuraminidase inhibitor susceptibility surveillance of influenza viruses circulating worldwide during the 2011 Southern Hemisphere season. Influenza Other Respir Viruses 7: 645– 658.
198. Russell RJ,, Haire LF,, Stevens DJ,, Collins PJ,, Lin YP,, Blackburn GM,, Hay AJ,, Gamblin SJ,, Skehel JJ. 2006. The structure of H5N1 avian influenza neuraminidase suggests new opportunities for drug design. Nature 443: 45– 49.
199. Collins PJ,, Haire LF,, Lin YP,, Liu J,, Russell RJ,, Walker PA,, Martin SR,, Daniels RS,, Gregory V,, Skehel JJ,, Gamblin SJ,, Hay AJ. 2009. Structural basis for oseltamivir resistance of influenza viruses. Vaccine 27: 6317– 6323.
200. Colman PM,, Hoyne PA,, Lawrence MC. 1993. Sequence and structure alignment of paramyxovirus hemagglutinin-neuraminidase with influenza virus neuraminidase. J Virol 67: 2972– 2980.
201. von Itzstein M. 2007. The war against influenza: discovery and development of sialidase inhibitors. Nature Rev Drug Discov 6: 967– 974.
202. Nguyen HT,, Fry AM,, Gubareva LV. 2012. Neuraminidase inhibitor resistance in influenza viruses and laboratory testing methods. Antivir Ther 17: 159– 173.
203. Zambon MC. 2013. Surveillance for antiviral resistance. Influenza Other Respir Viruses 7( Suppl 1) : 37– 43.
204. Zambon M,, Hayden FG, Global Neuraminidase Inhibitor Susceptibility Network . 2001. Position statement: global neuraminidase inhibitor susceptibility network. Antiviral Res 49: 147– 156.
205. McKimm-Breschkin JL,, Williams J,, Barrett S,, Jachno K,, McDonald M,, Mohr PG,, Saito T,, Tashiro M. 2013. Reduced susceptibility to all neuraminidase inhibitors of influenza H1N1 viruses with haemagglutinin mutations and mutations in non-conserved residues of the neuraminidase. J Antimicrob Chemother 68: 2210– 2221.
206. Whitley RJ,, Hayden FG,, Reisinger KS,, Young N,, Dutkowski R,, Ipe D,, Mills RG,, Ward P. 2001. Oral oseltamivir treatment of influenza in children. Pediatr Infect Dis J 20: 127– 133.
207. Kiso M,, Mitamura K,, Sakai-Tagawa Y,, Shiraishi K,, Kawakami C,, Kimura K,, Hayden FG,, Sugaya N,, Kawaoka Y. 2004. Resistant influenza A viruses in children treated with oseltamivir: descriptive study. Lancet 364: 759– 765.
208. McKimm-Breschkin J,, Trivedi T,, Hampson A,, Hay A,, Klimov A,, Tashiro M,, Hayden F,, Zambon M. 2003. Neuraminidase sequence analysis and susceptibilities of influenza virus clinical isolates to zanamivir and oseltamivir. Antimicrob Agents Chemother 47: 2264– 2272.
209. Dharan NJ,, Gubareva LV,, Meyer JJ,, Okomo-Adhiambo M,, McClinton RC,, Marshall SA,, St George K,, Epperson S,, Brammer L,, Klimov AI,, Bresee JS,, Fry AM, Oseltamivir-Resistance Working Group . 2009. Infections with oseltamivir-resistant influenza A(H1N1) virus in the United States. JAMA 301: 1034– 1041.
210. Sheu TG,, Deyde VM,, Okomo-Adhiambo M,, Garten RJ,, Xu X,, Bright RA,, Butler EN,, Wallis TR,, Klimov AI,, Gubareva LV. 2008. Surveillance for neuraminidase inhibitor resistance among human influenza A and B viruses circulating worldwide from 2004 to 2008. Antimicrob Agents Chemother 52: 3284– 3292.
211. Chao DL. 2013. Modeling the global transmission of antiviral-resistant influenza viruses. Influenza Other Respir Viruses 7( Suppl 1) : 58– 62.
212. Bloom JD,, Gong LI,, Baltimore D. 2010. Permissive secondary mutations enable the evolution of influenza oseltamivir resistance. Science 328: 1272– 1275.
213. Ives JA,, Carr JA,, Mendel DB,, Tai CY,, Lambkin R,, Kelly L,, Oxford JS,, Hayden ,, Roberts NA. 2002. The H274Y mutation in the influenza A/H1N1 neuraminidase active site following oseltamivir phosphate treatment leave virus severely compromised both in vitro and in vivo. Antiviral Res 55: 307– 317.
214. Gooskens J,, Jonges M,, Claas EC,, Meijer A,, van den Broek PJ,, Kroe AMs. 2009. Morbidity and mortality associated with nosocomial transmission of oseltamivir-resistant influenza A(H1N1) virus. JAMA 301: 1042– 1046.
215. Whitley RJ,, Boucher CA,, Lina B,, Nguyen-Van-Tam JS,, Osterhaus A,, Schutten M,, Monto AS. 2013. Global assessment of resistance to neuraminidase inhibitors, 2008–2011: The Influenza Resistance Information Study (IRIS). Clin Infect Dis 56: 1197– 1205.
216. Hurt AC,, Hardie K,, Wilson NJ,, Deng YM,, Osbourn M,, Leang SK,, Lee RT,, Iannello P,, Gehrig N,, Shaw R,, Wark P,, Caldwell N,, Givney RC,, Xue L,, Maurer-Stroh S,, Dwyer DE,, Wang B,, Smith DW,, Levy A,, Booy R,, Dixit R,, Merritt T,, Kelso A,, Dalton C,, Durrheim D,, Barr IG. 2012. Characteristics of a widespread community cluster of H275Y oseltamivir-resistant A(H1N1)pdm09 influenza in Australia. J Infect Dis 206: 148– 157.
217. Leneva IA,, Goloubeva O,, Fenton RJ,, Tisdale M,, Webster RG. 2001. Efficacy of zanamivir against avian influenza A viruses that possess genes encoding H5N1 internal proteins and are pathogenic in mammals. Antimicrob Agents Chemother 45: 1216– 1224.
218. Leneva IA,, Roberts N,, Govorkova EA,, Goloubeva OG,, Webster RG. 2000. The neuraminidase inhibitor GS4104 (oseltamivir phosphate) is efficacious against A/Hong Kong/156/97 (H5N1) and A/Hong Kong/1074/99 (H9N2) influenza viruses. Antiviral Res 48: 101– 115.
219. de Jong MD,, Tran TT,, Truong HK,, Vo MH,, Smith GJ,, Nguyen VC,, Bach VC,, Phan TQ,, Do QH,, Guan Y,, Peiris JS,, Tran TH,, Farrar J. 2005. Oseltamivir resistance during treatment of influenza A (H5N1) infection. N Engl J Med 353: 2667– 2672.
220. Pizzorno A,, Abed Y,, Bouhy X,, Beaulieu E,, Mallett C,, Russell R,, Boivin G. 2012. Impact of mutations at residue I223 of the neuraminidase protein on the resistance profile, replication level, and virulence of the 2009 pandemic influenza virus. Antimicrob Agents Chemother 56: 1208– 1214.
221. Hurt AC,, Lee RT,, Leang SK,, Cui L,, Deng YM,, Phuah SP,, Caldwell N,, Freeman K,, Komadina N,, Smith D,, Speers ,, Kelso A,, Lin RT,, Maurer-Stroh S,, Barr IG. 2011. Increased detection in Australia and Singapore of a novel influenza A(H1N1)2009 variant with reduced oseltamivir and zanamivir sensitivity due to a S247N neuraminidase mutation. Euro Surveill 16: pii=19884.
222. Hurt AC,, Holien JK,, Parker M,, Kelso A,, Barr IG. 2009. Zanamivir-resistant influenza viruses with a novel neuraminidase mutation. J Virol 83: 10366– 10373.
223. Okomo-Adhiambo M,, Nguyen HT,, Abd Elal A,, Sleeman K,, Fry AM,, Gubareva LV. 2014. Drug susceptibility surveillance of influenza viruses circulating in the United States in 2011–2012: application of the WHO antiviral working group criteria. Influenza Other Respir Viruses 8: 258– 265.
224. Ison MG,, Gubareva LV,, Atmar RL,, Treanor J,, Hayden FG. 2006. Recovery of drug-resistant influenza virus from immunocompromised patients: a case series. J Infect Dis 193: 760– 764.
225. Hu Y,, Lu S,, Song Z,, Wang W,, Hao P,, Li J,, Zhang X,, Yen HL,, Shi B,, Li T,, Guan W,, Xu L,, Liu Y,, Wang S,, Zhang X,, Tian D,, Zhu Z,, He J,, Huang K,, Chen H,, Zheng L,, Li X,, Ping J,, Kang B,, Xi X,, Zha L,, Li Y,, Zhang Z,, Peiris M,, Yuan Z. 2013. Association between adverse clinical outcome in human disease caused by novel influenza A H7N9 virus and sustained viral shedding and emergence of antiviral resistance. Lancet 381: 2273– 2279.
226. Gubareva LV,, Matrosovich MN,, Brenner MK,, Bethell RC,, Webster RG. 1998. Evidence for zanamivir resistance in an immunocompromised child infected with influenza B virus. J Infect Dis 178: 1257– 1262.

Tables

Mechanisms of Resistance to Antiviral Agents
[com.pub2web.rdf.cci.facet.ContentItem[id=http://asm.metastore.ingenta.com/content/author/10.1128/9781555817381.mcm11.ch111-1,webId=/content/author/10.1128/9781555817381.mcm11.ch111-1,properties={foaf_givenname=Robert W., foaf_name=Robert W. Shafer, foaf_surname=Shafer}], com.pub2web.rdf.cci.facet.ContentItem[id=http://asm.metastore.ingenta.com/content/author/10.1128/9781555817381.mcm11.ch111-2,webId=/content/author/10.1128/9781555817381.mcm11.ch111-2,properties={foaf_givenname=Sunwen, foaf_name=Sunwen Chou, foaf_surname=Chou}]]
Citation: Shafer R, Chou S. 2015. Mechanisms of Resistance to Antiviral Agents, p 1894-1912. In Jorgensen J, Pfaller M, Carroll K, Funke G, Landry M, Richter S, Warnock D (ed), Manual of Clinical Microbiology, Eleventh Edition. ASM Press, Washington, DC. doi: 10.1128/9781555817381.ch111
/content/10.1128/9781555817381.mcm11.ch111.ch111.tab001
TABLE 1

Mechanisms and mutations associated with herpesvirus antiviral drug resistance

Generic image for table
TABLE 1

Mechanisms and mutations associated with herpesvirus antiviral drug resistance

Citation: Shafer R, Chou S. 2015. Mechanisms of Resistance to Antiviral Agents, p 1894-1912. In Jorgensen J, Pfaller M, Carroll K, Funke G, Landry M, Richter S, Warnock D (ed), Manual of Clinical Microbiology, Eleventh Edition. ASM Press, Washington, DC. doi: 10.1128/9781555817381.ch111
/content/10.1128/9781555817381.mcm11.ch111.ch111.tab002
TABLE 2

Genetic mechanisms of resistance to antiretroviral agents

Generic image for table
TABLE 2

Genetic mechanisms of resistance to antiretroviral agents

Citation: Shafer R, Chou S. 2015. Mechanisms of Resistance to Antiviral Agents, p 1894-1912. In Jorgensen J, Pfaller M, Carroll K, Funke G, Landry M, Richter S, Warnock D (ed), Manual of Clinical Microbiology, Eleventh Edition. ASM Press, Washington, DC. doi: 10.1128/9781555817381.ch111
/content/10.1128/9781555817381.mcm11.ch111.ch111.tab003
TABLE 3

Genetic mechanisms of resistance to inhibitors of hepatitis B virus (HBV)

Generic image for table
TABLE 3

Genetic mechanisms of resistance to inhibitors of hepatitis B virus (HBV)

Citation: Shafer R, Chou S. 2015. Mechanisms of Resistance to Antiviral Agents, p 1894-1912. In Jorgensen J, Pfaller M, Carroll K, Funke G, Landry M, Richter S, Warnock D (ed), Manual of Clinical Microbiology, Eleventh Edition. ASM Press, Washington, DC. doi: 10.1128/9781555817381.ch111
/content/10.1128/9781555817381.mcm11.ch111.ch111.tab004
TABLE 4

Genetic mechanisms of resistance to hepatitis C virus inhibitors

Generic image for table
TABLE 4

Genetic mechanisms of resistance to hepatitis C virus inhibitors

Citation: Shafer R, Chou S. 2015. Mechanisms of Resistance to Antiviral Agents, p 1894-1912. In Jorgensen J, Pfaller M, Carroll K, Funke G, Landry M, Richter S, Warnock D (ed), Manual of Clinical Microbiology, Eleventh Edition. ASM Press, Washington, DC. doi: 10.1128/9781555817381.ch111
/content/10.1128/9781555817381.mcm11.ch111.ch111.tab005
TABLE 5

Genetic mechanisms of resistance to influenza virus inhibitors

Generic image for table
TABLE 5

Genetic mechanisms of resistance to influenza virus inhibitors

Citation: Shafer R, Chou S. 2015. Mechanisms of Resistance to Antiviral Agents, p 1894-1912. In Jorgensen J, Pfaller M, Carroll K, Funke G, Landry M, Richter S, Warnock D (ed), Manual of Clinical Microbiology, Eleventh Edition. ASM Press, Washington, DC. doi: 10.1128/9781555817381.ch111

Back to top
This is a required field
Please enter a valid email address
Please check the format of the address you have entered.
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error